T Cell Receptor Antagonist Peptides Induce Positive Selection

ArticleinCell 76(1):17-27 · February 1994with36 Reads
DOI: 10.1016/0092-8674(94)90169-4 · Source: PubMed
We have used organ culture of fetal thymic lobes from T cell receptor (TCR) transgenic beta 2M(-/-) mice to study the role of peptides in positive selection. The TCR used was from a CD8+ T cell specific for ovalbumin 257-264 in the context of Kb. Several peptides with the ability to induce positive selection were identified. These peptide-selected thymocytes have the same phenotype as mature CD8+ T cells and can respond to antigen. Those peptides with the ability to induce positive selection were all variants of the antigenic peptide and were identified as TCR antagonist peptides for this receptor. One peptide tested, E1, induced positive selection on the beta 2M(-/-) background but negative selection on the beta 2M(+/-) background. These results show that the process of positive selection is exquisitely peptide specific and sensitive to extremely low ligand density and support the notion that low efficacy ligands mediate positive selection.
    • "All mouse protocols were approved by the Animal Care Advisory Committee at the University of Victoria (permit number: 2011-032(2)), following Canadian Council for Animal Care guidelines. Adoptive cell transfer of splenocytes from female OT-I transgenic mice (Jackson Labs) containing T cells recognizing the chicken ovalbumin (OVA) 257-264 epitope SIINFEKL were used as positive controls for tumor bearing experiments[53]. Mouse mammary tumor virus MMTV/neu OT-I/OT-II transgenic mice were used as hosts in tumor-bearing experiments[54]. "
    [Show abstract] [Hide abstract] ABSTRACT: Due to advances in sequencing technology, somatically mutated cancer antigens, or neoantigens, are now readily identifiable and have become compelling targets for immunotherapy. In particular, neoantigen-targeted vaccines have shown promise in several pre-clinical and clinical studies. However, to date, neoantigen-targeted vaccine studies have involved tumors with exceptionally high mutation burdens. It remains unclear whether neoantigen-targeted vaccines will be broadly applicable to cancers with intermediate to low mutation burdens, such as ovarian cancer. To address this, we assessed whether a derivative of the murine ovarian tumor model ID8 could be targeted with neoantigen vaccines. We performed whole exome and transcriptome sequencing on ID8-G7 cells. We identified 92 somatic mutations, 39 of which were transcribed, missense mutations. For the 17 top predicted MHC class I binding mutations, we immunized mice subcutaneously with synthetic long peptide vaccines encoding the relevant mutation. Seven of 17 vaccines induced robust mutation-specific CD4 and/or CD8 T cell responses. However, none of the vaccines prolonged survival of tumor-bearing mice in either the prophylactic or therapeutic setting. Moreover, none of the neoantigen-specific T cell lines recognized ID8-G7 tumor cells in vitro, indicating that the corresponding mutations did not give rise to bonafide MHC-presented epitopes. Additionally, bioinformatic analysis of The Cancer Genome Atlas data revealed that only 12% (26/220) of HGSC cases had a ≥90% likelihood of harboring at least one authentic, naturally processed and presented neoantigen versus 51% (80/158) of lung cancers. Our findings highlight the limitations of applying neoantigen-targeted vaccines to tumor types with intermediate/low mutation burdens.
    Full-text · Article · May 2016
    • "Act-mOVA mice grafted with OT-I CD81 T cells develop acute GvHD-like symptoms Acute GvHD was induced by lethal dose TBI and subsequent aHSCT involving two transgenic, single minor allele mismatched, but otherwise syngeneic mouse strains as aHSC donors and recipients. To this end, C57Bl/6 ActmOVA mice (also known as CAG-OVA mice) [21] carrying an ubiquitously expressed membrane-bound chicken ovalbumin (OVA) transgene under the control of the CMV immediate-early enhancer and chicken beta-actin promoter, and displaying the OVA 254–267 (SIINFEKL) peptide in the context of H2-K b , were used as recipients; while C57Bl/6 OT-I animals [22] , featuring CD8? T cells with a transgenic TCR restricted to H2-K b -presented SIINFEKL peptides, were utilized as donors. Recipient mice were exposed to lethal dose TBI (11 Gy, in two split doses, 3 h apart), and on the same day (aHSCT ? "
    [Show abstract] [Hide abstract] ABSTRACT: T-cell receptor (TCR)-transgenic models of acute graft-versus-host disease (aGvHD) offer a straightforward and highly controlled approach to study the mechanisms and consequences of T-cell activation following allogeneic hematopoietic stem cell transplantation (aHSCT). Here, we report that aHSCT involving OT-I mice as donors, carrying an ovalbumin-specific CD8+ TCR, and Act-mOVA mice as recipients, expressing membrane-bound ovalbumin driven by the β-actin promoter, induces lethal aGvHD in a CD8+ T-cell-dependent, highly reproducible manner, within 4-7 days. Tracking of UBC-GFP/OT-I graft CD8+ T cells disclosed heavy infiltration of the gastrointestinal tract, liver, and lungs at the onset of the disease, and histology confirmed hallmark features of gastrointestinal aGVHD, hepatic aGvHD, and aGvHD-associated lymphocytic bronchitis in infiltrated organs. However, T-cell infiltration was virtually absent in the skin, a key target organ of human aGvHD, and histology confirmed the absence of cutaneous aGVHD, as well. We show that the model allows studying CD8+ T-cell responses in situ, as selective recovery of graft CD45.1/OT-I CD8+ T cells from target organs is simple and feasible by automated tissue dissociation and subsequent cell sorting. Assessment of interferon-gamma production by flow cytometry, granzyme-B release by ELISA, TREC assay, and whole-genome gene expression profiling confirmed that isolated graft CD8+ T cells remained intact, underwent clonal expansion, and exerted effector functions in all affected tissues. Taken together, these data demonstrate that the OT-I/Act-mOVA model is suitable to study the CD8+ T-cell-mediated effector mechanisms in a disease closely resembling fatal human gastrointestinal and hepatic aGVHD that may develop after aHSCT using HLA-matched unrelated donors.
    Full-text · Article · Apr 2016
    • "We next aimed to validate these results using the very potent OT-1 CTL expressing a transgenic TCR specific for chicken ovalbumin residues 257–264 in the context of H2K b MHC I molecule [36]. Day 6 OT-1 CTL also better killed mNS than GL261 at all the E:T ratio tested (Fig 5A). "
    Full-text · Dataset · Apr 2016 · Cellular and Molecular Life Sciences CMLS
Show more